vimarsana.com

Latest Breaking News On - Biosenic group - Page 4 : vimarsana.com

BioSenic provides update regarding current license agreement with Phebra

INSIDE INFORMATION Maintenance of the license is now subject to the launch of the OATO Phase III before May 2024 instead of 31 May 2023 Parties also currently negotiating a potential renegotiation. | May 29, 2023

Mont saint guibertWaals gewestFrance generalGhislaine gasparettoBert bouserieNeil hunter michelle boxallAnnie florence loyerSeitosei actifinPhebra pty ltdInternational media enquiriesIb communicationsBiosenic groupEuronext brusselsGraft versus host diseaseSystemic sclerosisSystemic lupus erythematosus

BioSenic provides first quarter 2023 business update

BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces its business update for the first quarter, ended 31 March 2023. Key highlights. Strengthening of Executive Committee and Board of Directors with the .

France generalMont saint guibertWaals gewestBiosenic groupEuronext brusselsExecutive committeeChief scientific officerChief medical officerYves sagotMarketing authorizationMarketing authorization applicationConvertible bondsSenic groupArsenic trioxideHost diseaseSystemic sclerosis

BioSenic provides First Quarter 2023 Business Update

REGULATED INFORMATION ALLOB Phase IIb topline results foreseen in July/August 2023Ongoing discussions for key partnerships with lead clinical assets Mont-Saint-Guibert, Belgium, May 22nd,. | May 22, 2023

France generalMont saint guibertWaals gewestSeitosei actifinNeil hunter michelle boxallBert bouserieGhislaine gasparettoAnnie florence loyerIb communicationsBiosenic groupInternational media enquiriesEuronext brusselsExecutive committeeChief scientific officerChief medical officerYves sagot

BioSenic receives key European patent from EPO, for further therapeutic development in cancer, infectious and immune diseases

INSIDE INFORMATION Patent covers the therapeutic use of a new composite formulation of anti-inflammatory compounds with unique advantages BioSenic’s new formulation lowers the dosage of. | April 18, 2023

Mont saint guibertWaals gewestFrance generalLouvain la neuveRegion flamandeAnnie florence loyerMichelle boxallSeitosei actifinNeil hunterBert bouserieGhislaine gasparettoBiosenic groupEuropean patent officeIb communicationsInternational media enquiriesEuronext brussels

BioSenic provides Financial Update and Financial Calendar 2023

INSIDE INFORMATION Mont-Saint-Guibert, Belgium, March 31, 2023, 7am CET - BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in severe autoimmune/inflammatory diseases

France generalMont saint guibertWaals gewestGhislaine gasparettoStefan klotterBert bouserieNeil hunter michelle boxallAnnie florence loyerSeitosei actifinInternational media enquiriesIb communicationsBiosenic groupNeither the companyEuronext brusselsYear resultsAnnual report

vimarsana © 2020. All Rights Reserved.